Posted by Michael Wonder on 09 Feb 2021
Scottish approval of a new treatment for people with chronic obstructive pulmonary disease - formoterol fumarate dihydrate/glycopyrronium bromide/budesonide
8 February 2021 - AstraZeneca today announced that Trixeo Aerosphere (formoterol fumarate/glycopyrronium bromide/budesonide) is now accepted for use by the SMC as a new option for maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist or combination of a long-acting beta2-agonist and a long-acting muscarinic antagonist.
The SMC is funding this new treatment in patients with chronic obstructive pulmonary disease whose forced expiratory volume in one second is less than 50%.
